A boutique venture capital firm is based in the Western United States. The firm invests in growth and expansion-stage technology and life science companies. The firm closed its second fund in 2015. The firm prefers to make growth stage investments in Series B, C and D rounds, typically co-investing with other institutional investors. The firm leads about 30% of the investment rounds it takes part in, with allocation sizes varying according to the needs of the round. The firm focuses on companies located in Southern California and other regions underserved by venture capital such as Utah, etc. The firm is actively seeking new investment opportunities, and anticipates that the second fund will invest in over 15 companies.

In the Life Sciences, the firm seeks to invest in diagnostics, therapeutics, and also selectively in medical device opportunities. The firm is opportunistic in terms of subsectors and indications. The firm generally seeks therapeutics that are at least in Phase III and diagnostics and medical devices that are very close to or with FDA approval. The firm historically invested in vitro diagnostic tests and medical imaging.

The firm generally co-invests with top tier institutional investors, and for companies based in Southern California the firm may act as a local lead investor to bring a syndicate together. The firm seeks companies with a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialty pharmaceutical company is headquartered in China with offices in Hong Kong and California. The company focuses on product development and sales and marketing in four therapeutic areas: clinical nutrition, oncology, antibiotics and respiratory system. The company is interested in forming partnerships with biopharmaceutical companies that are interested in entering the Chinese market. The company is flexible in terms of partnering models, which includes in-licensing, co-development, exclusive distribution, joint venture, and product acquisition. The company is actively seeking products from the US and Europe.

The company is currently seeking products in the following therapeutic areas: oncology, respiratory system, antibiotics, clinical nutrition, and cardiovascular. However, the company is equally interested in other areas with unmet medical needs in China (such as CNS, GI, Nephrology, etc). The company will consider both small molecules and biologics. The firm is most interested in NCE or NCE-like molecules. The firm will only consider biosimilar or generics if there are no similar products or very few players with identical chemical/biological structure in China. In terms of phase of development, the firm will consider marketed and early-late clinical stage products for the five listed areas above. For other therapeutic areas, the company is looking for assets that have obtained regulatory approval in the US or Europe markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm with bases in Hong Kong and the United States is primarily focused on healthcare investments with a particular interest in the life science space. The firm looks to make allocations ranging from $250,000 as the first round in a tranched financing structure to $20 million over the lifetime of the investment and depending on the financial needs of the company. The firm is actively seeking new investments and is open to review opportunities from around the globe.

Within the life science space the firm is interested in therapeutics, medical devices, and diagnostics. The firm is currently most interested in companies with some clinical data however they are open to reviewing pre-clinical stage opportunities as well. The firm is open to biosimilar and repurposed assets, and has a preference for platform technologies but is also open to considering single asset opportunities. The firm is open to review all classes of medical devices and diagnostics. The firm is entirely open in terms of indication.

The firm is open to investing in both private and publically help companies and is currently very interested in making cross over investments. The firm is also very interested in companies that have a plan or ability to enter the Chinese market as the firm can add significant value with this strategy. The firm is open to acting as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A hybrid venture capital and hedge fund is managed by a firm based in the Western United States. The firm is currently looking to make investments into biotech companies. The firm is looking to make investments ranging from $1-5 million generally in Seed and Series A rounds. The firm is open to reviewing opportunities from throughout the United States and Canada.

The firm is currently looking for companies working with therapeutics. The firm is open to reviewing both small molecules and biologics and in terms of indication is focused exclusively on oncology, in particular prostate cancer, and immunology. The firm is open to reviewing company’s at all therapeutic phases of development however they prefer smaller valuations.

The firm is open to working with public or privately held companies and looks for companies with experienced management teams. The firm looks to add significant value in addition to capital including the expertise and connections of the firm’s partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture fund formed by a group of high net-worth individuals in China is currently seeking investment opportunities globally with a focus on China and US. Projects based in Canada, Germany, and Switzerland may also be considered. The fund pays close attention to investment opportunities from seed and early stage to growth stage. For seed and early stage projects, the fund makes investments in convertible notes and equity and is flexible on investment size. For growth stage projects, the fund makes equity investments of US$1-5 million in businesses with valuation of up to US$18-20 million. The fund typically syndicates with co-investors. The fund would like to partner with local investors in case of overseas investments.

The fund focuses on high-growth fields in medical devices, diagnostics, digital health, and consumer products and is agnostic to therapeutic areas. In diagnostics, the fund is interested in portable imaging devices, high-intensity ultrasound, point-of-care diagnostics, and molecular diagnostics. In digital health, the fund is interested in technologies that can be applicable to the Chinese market, such as connected devices, telemedicine, and patient-physician platforms. In consumer products, the fund in interested in OTC, nutrition, and dietary supplements that have proven efficacy and are on market.

The fund is looking to work with serial entrepreneurs from seed and early stages to growth stage to form complete and strong teams. The fund typically cooperates with local co-investors who play a supervisory role in overseas operations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A European VC firm with over €700 million in total assets under management, and has raised a total of five funds; the most recent fund closed in 2014. The firm typically invests €1-5 million in venture-stage opportunities, or up to €15 million in growth-stage opportunities. The firm is open to opportunities globally and has invested in Western and Eastern Europe, the Middle East and the USA.

Within the life science sector the firm is currently focused on medical technology, diagnostics, life science tools, and digital health. The firm is open to all classes of devices and molecules, is open to opportunities in any indication area and at any phase of development. Previous investments include diagnostics for stroke, Nano coatings for implants, and cardiovascular catheters.

The firm is open to investing in pre-revenue companies, companies at the early commercialization stage, as well companies generating steady revenues.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm founded in 2012 with offices in Eastern and Western US and Ireland is currently looking to make new investments into biopharmaceutical and medical device companies from its $172 million fund. The firm looks to invest in companies in seed to series B rounds and can provide up to about $17 million to a company over the lifetime of the investment. The firm is most interested in companies based in the US, Canada, and Ireland and will also consider exceptional opportunities elsewhere in Europe and in Asia. The firm plans to make approximately 4-5 new investments over the next 6-9 months.

The firm is interested in companies developing either biopharmaceuticals or medical devices. For biopharmaceuticals, the firm is interested in all modalities including small molecules, biologics, and cell and gene therapies. The firm is primarily interested in platform companies with the potential for multiple assets and strongly prefers technologies to be 1^st in class or best in class, often originating from breakthrough chemistry or biology discoveries. The firm is looking for companies with assets in preclinical development through Phase 1 clinical trials. For medical devices, the firm is primarily interested in companies working on devices that are therapeutic in nature, as well as devices for self-pay markets, including aesthetics. The firm is indication-agnostic in both biopharmaceuticals and devices.

The firm can both lead and co-lead investments, with a preference for taking a board seat. The firm prefers working with management teams with positive track records; however, they are open to working with incomplete or non-permanent management teams as well, especially for very early stage opportunities. The firm’s team has extensive operating experience and deep networks, which they can leverage to support companies as needed.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com